"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03169231","Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty",,"Completed","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo","Longeveron Inc.","All","70 Years to 85 Years   (Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001-03","July 6, 2017","September 30, 2021","September 30, 2021","May 30, 2017",,"March 7, 2022","Soffer Health Institute, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03169231"
2,"NCT02982915","Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty","HERA","Completed","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Biological: Fluzone High Dose Vaccine","The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause|Falls Efficacy Scale-International (FES-I)|Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:|Rate of decline in Aging Frailty status as assessed by the 6 minute walk test|Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)|Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test|Rate of decline in Aging Frailty status as assessed by the Weight Loss|Rate of decline in Aging Frailty status as assessed by the Handgrip Test","Longeveron Inc.","All","65 Years to 90 Years   (Older Adult)","Phase 1|Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-03","November 2016","June 2021","June 2022","December 6, 2016",,"August 17, 2022","Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Miami, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Optimal Research LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02982915"
3,"NCT03525418","Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)","ELPIS","Completed","No Results Available","HLHS","Biological: Longeveron Mesenchymal Stem Cells","Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.","Longeveron Inc.","All","1 Day to 1 Year   (Child)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-05","February 21, 2018","December 31, 2021","December 31, 2021","May 15, 2018",,"March 7, 2022","Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03525418"
4,"NCT02600130","Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo","To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.","Longeveron Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00-0000-01","October 10, 2016","September 2020","September 2021","November 9, 2015",,"December 14, 2021","Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02600130"
5,"NCT04629105","Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)","RECOVER","Recruiting","No Results Available","ARDS, Human|Covid19","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography","Longeveron Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-006","July 24, 2020","August 2023","July 2025","November 16, 2020",,"September 30, 2021","Miami VA Healthcare System, Miami, Florida, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04629105"
